GlassScriptPhysician profile
Anthony Inguaggiato
NPI 1336219948
$817.86
in general payments reported to CMS, 2019-2025
11 companies · $35.88 in 2025
The $35.88 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $184 · 2021: $23.98 · 2022: $58.11 · 2023: $30.22 · 2024: $154 · 2025: $35.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $220.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.92 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $148.51 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $94.03 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $72.90 | 2024 | Verquvo |
| Tactile Systems Technology INC | $36.30 | 2019 | |
| Boston Scientific Corporation | $34.96 | 2019-2020 | |
| G Medical Diagnostic Services, INC. | $31.64 | 2019 | |
| Pfizer INC. | $29.41 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.19 | 2025 | |
| Allergan, INC. | $15.00 | 2019 | |
| Bardy Diagnostics, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Inguaggiato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.